Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis

Azza Sarfraz , Muzna Sarfraz , Faheem Javad , Musfira Khalid , Bushra Shah , Amna Gul , Mohammad Arfat Ganiyani , Areeba Ismail , Khadija Cheema

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002293

PDF (1425KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002293 DOI: 10.37349/etat.2025.1002293
Meta-Analysis
research-article
Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis
Author information +
History +
PDF (1425KB)

Abstract

Background: Breast cancer is a leading cause of mortality in women. Hormone therapy plays a crucial role in treatment of hormone receptor-positive metastatic breast cancer. Elacestrant is a selective estrogen receptor degrader (SERD) that has shown promise in early-phase clinical trials. This post-hoc analysis systematically evaluates elacestrant’s effectiveness in hormone receptor-positive metastatic breast cancer patients, providing insights into its efficacy, safety, and potential advantages over existing treatments.

Methods: We adhered to the PRISMA Statement 2020 guidelines and systematically searched the databases PubMed/MEDLINE, ClinicalTrials.gov, Web of Science, and Embase. We conducted the post-hoc analysis using R software (V 4.3.3), applying the inverse variance method and the DerSimonian-Laird estimator to pool effect estimates with a random-effects model. We assessed heterogeneity using the Cochran’s Q test and the I2 statistic.

Results: Our post-hoc analysis encompassed 3 clinical trials and a total of 835 participants. The mean age of all 835 participants across the three trials was 59.5 years (95% CI: 58.7–60.3). The pooled progression-free survival (PFS)-was estimated at 4.38 (95% CI: –7.58–16.35, P = 0.47), and the pooled objective response rate (ORR) was 7% (95% CI: 2–18%, P = 0.04), with significant heterogeneity observed among the studies. Discussion: Elacestrant shows promise for improving outcomes in hormone receptor-positive metastatic breast cancer, but further research is needed to confirm its effectiveness. Future studies should include larger sample sizes, comprehensive phase II and III trials, and investigation of elacestrant in combination with other drugs or in preoperative settings.

Keywords

Elacestrant / selective estrogen receptor degraders / breast cancer / antineoplastic agents / hormone receptor-positive

Cite this article

Download citation ▾
Azza Sarfraz, Muzna Sarfraz, Faheem Javad, Musfira Khalid, Bushra Shah, Amna Gul, Mohammad Arfat Ganiyani, Areeba Ismail, Khadija Cheema. Elacestrant in hormone receptor-positive metastatic breast cancer: a post-hoc analysis. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002293 DOI:10.37349/etat.2025.1002293

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, et al. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. 2018; 132: 47-68.

[2]

Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012; 26: 688-94, 696.

[3]

Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002; 137: 678-87.

[4]

Elayoubi J, Chi J, Mahmoud AA, Alloghbi A, Assad H, Shekhar M, et al. A Review of Endocrine Therapy in Early-stage Breast Cancer: The Journey From Crudeness to Precision. Am J Clin Oncol. 2023; 46: 225-30.

[5]

Al-Qasem AJ, Alves CL, Ditzel HJ. Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2- Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies. Cancers (Basel). 2021; 13: 5397.

[6]

Lainé M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021; 23: 54.

[7]

Sanchez KG, Nangia JR, Schiff R, Rimawi MF. Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022; 40: 3227-9.

[8]

Li Y, Orahoske CM, Urmetz SM, Zhang W, Huang Y, Gan C, et al. Identification of estrogen receptor down-regulators for endocrine resistant breast cancer. J Steroid Biochem Mol Biol. 2022; 224: 106162.

[9]

Pancholi S, Simigdala N, Ribas R, Schuster E, Leal MF, Nikitorowicz-Buniak J, et al. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer. NPJ Breast Cancer. 2022; 8: 125.

[10]

Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018; 186: 1-24.

[11]

Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, et al. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017; 23: 4793-804.

[12]

ORSERDUTM (elacestrant) tablets, for oral use Initial U.S. Approval: 2023 [Internet]. [Cited 2023 Mar 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf

[13]

Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, et al. US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer. J Clin Oncol. 2024; 42: 1193-201.

[14]

Foong SYF, Simpson PT, Cummings MC, Lakhani SR. Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. In: Shin SJ, Chen YY, Ginter PS, editors. A Comprehensive Guide to Core Needle Biopsies of the Breast. Springer, Cham; 2022. pp. 895-915.

[15]

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021; 18: e1003583.

[16]

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022; 40: 3246-56.

[17]

Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, et al. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021; 39: 1360-70.

[18]

Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, et al. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using18F-FES PET/CT imaging. Breast Cancer Res. 2020; 22: 97.

[19]

Varella L, Cristofanilli M. Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date. Onco Targets Ther. 2023; 16: 189-96.

[20]

Olivier T, Prasad V. Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? Transl Oncol. 2022; 15: 101273.

[21]

Kaklamani VG, Bidard FC, Neven P, Montero AJ, Mouret-Reynier MA, Sohn J, et al. Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET). J Clin Oncol. 2023; 41: 16.

[22]

Jacobson A. Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer. Oncologist. 2022; 27: S7-8.

[23]

Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, et al. Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells. Breast Cancer Res Treat. 2023; 201: 43-56.

[24]

Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, et al. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs. 2022; 31: 515-29.

[25]

Wardell SE, Nelson ER, Chao CA, Alley HM, McDonnell DP. Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader. Endocr Relat Cancer. 2015; 22: 713-24.

[26]

Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015; 26: 948-56.

[27]

Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women. Eur J Drug Metab Pharmacokinet. 2020; 45: 675-89.

[28]

Elacestrant Dihydrochloride. Am J Health Syst Pharm. 2023; 80: 643-5.

[29]

Beumer JH, Foldi J. Pharmacology and pharmacokinetics of elacestrant. Cancer Chemother Pharmacol. 2023; 92: 157-63.

[30]

Zhou F, Yang G, Xue L, Liu Y, Guo Y, Zhu J, et al. SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models. Breast Cancer Res. 2023; 25: 96.

[31]

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. ; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134: e48-72.

[32]

Hoy SM. Elacestrant: First Approval. Drugs. 2023; 83: 555-61.

[33]

Zhong Y, Ding B, Qian L, Wu W, Wen Y. Hormone Receptor Expression on Endocrine Therapy in Patients with Breast Cancer: A Meta-Analysis. Am Surg. 2022; 88: 48-57.

[34]

Wang Y, Tang SC. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev. 2022; 41: 975-90.

[35]

Rostoft S, van den Bos F, Pedersen R, Hamaker ME. Shared decision-making in older patients with cancer - What does the patient want? J Geriatr Oncol. 2021; 12: 339-42.

PDF (1425KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉